PAQR3在肝细胞癌中的表达及其与T淋巴细胞免疫浸润、免疫检查点基因及患者生存期关系的生物信息学分析

doi:10.13481/j.1671-587X.20260320

Abstract

Abstract:

Objective To discuss the expression of progestin and adipoQ receptor 3 （PAQR3） in hepatocellular carcinoma （HCC） and its association with immune infiltration， immunotherapy response， and patient survival， and to clarify its role in the HCC immune microenvironment and its clinical significance. Methods The HCC tissue and adjacent tissue samples were collected from 3 cases of HCC patients who underwent hepatectomy in General Hospital of Tianjin Medical University from January to December 2023. Western blotting method and immunohistochemical staining were used to detect the expression level of PAQR3 protein in HCC tissue and adjacent tissue of each HCC patient. The gene expression and clinical data of HCC patients who underwent hepatectomy were collected from The Cancer Genome Atlas （TCGA） database. Various algorithms such as CIBERSORT and TIMER2.0 were used to analyze the correlation between PAQR3 expression and immune cell infiltration； Spearman correlation analysis was used to evaluate the correlation between PAQR3 expression level and the expression levels of immune checkpoint genes ［programmed cell death protein 1 （PDCD1）， cluster of differentiation 274 （CD274）， and cytotoxic T-lymphocyte?associated protein 4 （CTLA4）］； Cox proportional hazards regression model and Kaplan-Meier method were used to analyze the relationship between PAQR3 protein expression and patient survival. Results The Western blotting and immunohistochemical staining results showed that compared with adjacent tissue， the expression level of PAQR3 protein in HCC tissue was significantly increased （P<0.05）. The TCGA database analysis results showed that compared with adjacent tissue， the expression of PAQR3 gene in HCC tissue was up?regulated （P<0.05）. The correlation analysis results showed that PAQR3 expression level was positively correlated with regulatory T cells （Tregs）（rho=0.349， P<0.001）， CD8⁺ T lymphocytes （rho=0.268， P<0.001）， M2 macrophages （rho=0.435， P<0.001）， and neutrophils （rho=0.399， P<0.001） in HCC tissue. High expression of PAQR3 protein was associated with shortened overall survival of HCC patients （P=0.019）， while immune infiltration was not associated with the survival of HCC patients （P>0.05）. The expression of PAQR3 was positively correlated with the expressions of immune checkpoint-related genes PDCD1， CD274， and CTLA4 （P<0.05）. Conclusion The expression of PAQR3 is up-regulated in HCC tissue. Its expression level is associated with the infiltration degree of various immune cells such as T lymphocytes and macrophages， the expression of immune checkpoint genes， and poor prognosis of patients， suggesting that PAQR3 may serve as a potential prognostic biomarker for HCC.

Key words: Progestin and adipoQ receptor 3, Hepatocellular carcinoma, Immune cell infiltration, Immune checkpoint genes, Bioinformatics analysis

CLC Number:

R730.2

Xiaohui LIANG,Wenna LIU,Jianbo ZHAO. Bioinformatic analysis on PAQR3 expression in hepatocellular carcinoma and its correlations with T lymphocyte infiltration, immune checkpoint genes, and patient survival[J].Journal of Jilin University(Medicine Edition), 2026, 52(3): 781-790.

Figures/Tables 9

Fig. 1

Fig. 2

Fig. 3

Tab.1

Tab.2

Tab.3

Fig. 4

Fig. 5

Fig. 6

References 27

[1]	SONG X X， ZHANG W M， YU N S， et al. PAQR3 facilitates the ferroptosis of diffuse large B-cell lymphoma via the regulation of LDLR-mediated PI3K/AKT pathway［J］. Hematol Oncol， 2024， 42（1）： e3219.
[2]	LUO J R， MEI Z X， LIN S， et al. Integrative pan-cancer analysis reveals the importance of PAQR family in lung cancer［J］. J Cancer Res Clin Oncol， 2023， 149（12）： 10149-10160.
[3]	GUO Q， LIU X L， ZHAI K， et al. The emerging roles and mechanisms of PAQR3 in human cancer： pathophysiology and therapeutic implications［J］. Int J Gen Med， 2023， 16： 4321-4328.
[4]	PINTER M， JAIN R K， DUDA D G. The current landscape of immune checkpoint blockade in hepatocellular carcinoma： a review［J］. JAMA Oncol， 2021， 7（1）： 113.
[5]	DONNE R， LUJAMBIO A. The liver cancer immune microenvironment： Therapeutic implications for hepatocellular carcinoma［J］. Hepatology， 2023， 77（5）： 1773-1796.
[6]	SINGAL A G， KUDO M， BRUIX J. Breakthroughs in hepatocellular carcinoma therapies［J］. Clin Gastroenterol Hepatol， 2023， 21（8）： 2135-2149.
[7]	YAHOO N， DUDEK M， KNOLLE P， et al. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation［J］. J Hepatol， 2023， 79（2）： 538-551.
[8]	RIMASSA L， FINN R S， SANGRO B. Combination immunotherapy for hepatocellular carcinoma［J］. J Hepatol， 2023， 79（2）： 506-515.
[9]	POLYZOS S A， CHRYSAVGIS L， VACHLIOTIS I D， et al. Nonalcoholic fatty liver disease and hepatocellular carcinoma： Insights in epidemiology， pathogenesis， imaging， prevention and therapy［J］. Semin Cancer Biol， 2023， 93： 20-35.
[10]	PINTER M， SCHEINER B， PINATO D J. Immune checkpoint inhibitors in hepatocellular carcinoma： emerging challenges in clinical practice［J］. Lancet Gastroenterol Hepatol， 2023， 8（8）： 760-770.
[11]	GRETEN T F， VILLANUEVA A， KORANGY F， et al. Biomarkers for immunotherapy of hepatocellular carcinoma［J］. Nat Rev Clin Oncol， 2023， 20（11）： 780-798.
[12]	LLOVET J M， WILLOUGHBY C E， SINGAL A G， et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma： pathogenesis and treatment［J］. Nat Rev Gastroenterol Hepatol， 2023， 20（8）： 487-503.
[13]	SINGAL A G， KANWAL F， LLOVET J M. Global trends in hepatocellular carcinoma epidemiology： implications for screening， prevention and therapy［J］. Nat Rev Clin Oncol， 2023， 20（12）： 864-884.
[14]	LING Z N， HONG L L， WU J， et al. Systematic pan-cancer analyses of the potential function of the Golgi scaffold protein PAQR3［J］. Sci Rep， 2024， 14（1）： 3030.
[15]	WU H G， ZHANG W J， DING Q， et al. Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma［J］. Oncol Rep， 2014， 32（6）： 2687-2695.
[16]	WU J Y， CHAN Y T， LU Y J， et al. The tumor microenvironment in the postsurgical liver： Mechanisms and potential targets of postoperative recurrence in human hepatocellular carcinoma［J］. Med Res Rev， 2023， 43（6）： 1946-1973.
[17]	CHEN Y W， ZHOU Y H， YAN Z Y， et al. Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma［J］. Cell Oncol （Dordr）， 2023， 46（6）： 1595-1604.
[18]	LI Z S， ZHANG Z H， FANG L T， et al. Tumor microenvironment composition and related therapy in hepatocellular carcinoma［J］. J Hepatocell Carcinoma， 2023， 10： 2083-2099.
[19]	CHEN S Q， DU Y Q， GUAN X Y， et al. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma［J］. Front Oncol， 2023， 13： 1204513.
[20]	YUAN Y， WU D L， LI J， et al. Mechanisms of tumor-associated macrophages affecting the progression of hepatocellular carcinoma［J］. Front Pharmacol， 2023， 14： 1217400.
[21]	ARGENTIERO A， DELVECCHIO A， FASANO R， et al. The complexity of the tumor microenvironment in hepatocellular carcinoma and emerging therapeutic developments［J］. J Clin Med， 2023， 12（23）： 7469.
[22]	YANG Q Q， TIAN H， GUO Z Y， et al. The role of noncoding RNAs in the tumor microenvironment of hepatocellular carcinoma［J］. Acta Biochim Biophys Sin， 2023， 55（11）： 1697-1706.
[23]	GAMBOA A C， KOOBY D A， MAITHEL S K， et al. Immune checkpoint inhibitors in hepatocellular carcinoma： a review of current clinical trials［J］. J Surg Oncol， 2024， 129（1）： 63-70.
[24]	PELIZZARO F， FARINATI F， TREVISANI F. Immune checkpoint inhibitors in hepatocellular carcinoma： current strategies and biomarkers predicting response and/or resistance［J］. Biomedicines， 2023， 11（4）： 1020.
[25]	RUFF S M， MANNE A， CLOYD J M， et al. Current landscape of immune checkpoint inhibitor therapy for hepatocellular carcinoma［J］. Curr Oncol， 2023， 30（6）： 5863-5875.
[26]	FOY V， MCNAMARA M G， VALLE J W， et al. Current evidence for immune checkpoint inhibition in advanced hepatocellular carcinoma［J］. Curr Oncol， 2023， 30（9）： 8665-8685.
[27]	CHAMI P， DIAB Y， KHALIL D N， et al. Radiation and immune checkpoint inhibitors： combination therapy for treatment of hepatocellular carcinoma［J］. Int J Mol Sci， 2023， 24（23）： 16773.

Infiltration	Rho	P	Adj.P
T cell CD4⁺ Th1 XCELL	-0.418	<0.001	<0.001
T cell regulatory (Tregs) QUANTISEQ	0.349	<0.001	<0.001
T cell CD4⁺ memory XCELL	0.265	<0.001	<0.001
T cell CD8⁺ TIMER	0.268	<0.001	<0.001
T cell CD4⁺ EPIC	0.243	<0.001	<0.001
T cell regulatory (Tregs) XCELL	0.234	<0.001	<0.001
T cell CD8⁺ na?ve XCELL	-0.234	<0.001	<0.001
T cell CD4⁺ memory resting CIBERSORT-ABS	0.205	<0.001	0.001
T cell CD4⁺ na?ve XCELL	-0.196	<0.001	0.001
T cell CD4⁺ Th2 XCELL	0.131	0.015	0.039
T cell CD4⁺ na?ve CIBERSORT	-0.130	0.016	0.043
T cell CD4⁺ na?ve CIBERSORT-ABS	-0.129	0.016	0.043
T cell CD4⁺ central memory XCELL	-0.128	0.018	0.045
T cell regulatory (Tregs) CIBERSORT-ABS	0.125	0.021	0.048

Infiltration	Rho	P	Adj.P
Macrophage M2 CIBERSORT-ABS	0.435	<0.001	<0.001
Macrophage M2 TIDE	－0.422	<0.001	<0.001
Macrophage M2 QUANTISEQ	0.345	<0.001	<0.001
Macrophage M1 CIBERSORT-ABS	0.339	<0.001	<0.001
Macrophage EPIC	－0.327	<0.001	<0.001
Macrophage/Monocyte MCPCOUNTER	0.320	<0.001	<0.001
Macrophage/Monocyte MCPCOUNTER	0.320	<0.001	<0.001
Monocyte MCPCOUNTER	0.320	<0.001	<0.001
Macrophage TIMER	0.264	<0.001	<0.001
Macrophage M1 QUANTISEQ	0.246	<0.001	<0.001
Monocyte CIBERSORT	－0.164	0.002	0.015
Macrophage M1 CIBERSORT	0.151	0.005	0.020
Macrophage M2 CIBERSORT	0.145	0.007	0.025

Infiltration	Rho	P	Adj.P
Neutrophil MCPCOUNTER	0.399	<0.001	<0.001
Neutrophil TIMER	0.370	<0.001	<0.001
Neutrophil QUANTISEQ	0.342	<0.001	<0.001
Myeloid dendritic cell TIMER	0.261	<0.001	<0.001
B cell QUANTISEQ	0.262	<0.001	<0.001
Myeloid dendritic cell MCPCOUNTER	0.252	<0.001	<0.001
NK cell activated CIBERSORT-ABS	0.209	<0.001	0.001
NK cell MCPCOUNTER	0.180	0.001	0.005
Neutrophil CIBERSORT-ABS	0.169	0.002	0.006
Plasmacytoid dendritic cell XCELL	-0.157	0.003	0.020
Neutrophil CIBERSORT	0.135	0.012	0.034
B cell EPIC	0.135	0.012	0.049

Bioinformatic analysis on PAQR3 expression in hepatocellular carcinoma and its correlations with T lymphocyte infiltration, immune checkpoint genes, and patient survival

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 27

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Gengfei CAO, SHAYA·Mahati,Junpeng GU,Weizheng JI, ASIHAER·Hasimu,Weixin REN. Differences in immune microenvironment between DEB-TACE and c-TACE in treatment of hepatocellular carcinoma and mechanism of TRADD-mediated Th17 differentiation [J]. Journal of Jilin University(Medicine Edition), 2026, 52(3): 764-780.
[2]	Xiqian ZHANG,Zhibo DANG,Yunan DU,Pei WU,Hang XIE,Gaofeng TAN. Inhibitory effect of Chaiqi Yigan formula on malignant biological behaviors of liver cancer HepG2 cells by regulating macrophage polarization [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 398-409.
[3]	Jiaxin WANG,Junwen MAO,Xuan ZHANG. Expression of natural autoantibodies against apoptosis inhibitory genes in plasma of patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2026, 52(1): 228-235.
[4]	Limei WEN,Yali GUO,Wenmei MA,Taotao XUE,Ruoyu GENG,Chong MA,Xinhong ZHANG,Jianhua YANG. Bioinformatic analysis of TCGA database based on INPP4B gene expression in hepatocellular carcinoma and its experimental validation [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1618-1629.
[5]	Yu LIANG,Jinyu YU,Zhonggao XU,Wanning WANG. Expression characteristics of FOSB in kidney tissue from IgA nephropathy and other common kidney diseases [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1281-1292.
[6]	Han LIN,Qiuyan YANG,Jieyue ZHONG,Bolun CHEN,Wangxia TONG. Improvement effect of cordycepin on ferroptosis in HepG2 cells induced by RSL3 and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 576-589.
[7]	Wenchang CAI,Yuqi LIU,Han WANG,Helin WANG,Zhenjiang WANG,Zishen XIAO,Shiyuan MA,Liping AN,Yanbo LIU. Expression of protein kinase D2 in bladder cancer tissue and its effect on tumor immune microenvironment [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 378-391.
[8]	Xiaoyan WANG,Xuelian LI,Bin LIANG,Wenfei TIAN,Hailin MA,Zhijing MO. Analysis on relationship between CALU and prognosis of hepatocellular carcinoma patients and its mechanism based on transcriptome and single cell sequencing data [J]. Journal of Jilin University(Medicine Edition), 2025, 51(2): 447-459.
[9]	Yongjing YANG,Tianyang KE,Shixin LIU,Xue WANG,Dequan XU,Tingting LIU,Ling ZHAO. Synergistic sensitization of apatinib mesylate and radiotherapy on hepatocarcinoma cells invitro [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1009-1015.
[10]	Jinlian LI,Lanzhen HUANG,Xishi HUANG,Kangzhi LI,Jiali JIANG,Miaomiao ZHANG,Qunying WU. Bioinformatics analysis on key genes related to prognosis, diagnosis， and immune cell infiltration of hepatocellular carcinoma and their potential therapeutic drugs [J]. Journal of Jilin University(Medicine Edition), 2024, 50(4): 1062-1075.
[11]	Xiaoyan WANG,Hao ZHANG,Zehao GUO,Jun CAO,Zhijing MO. Screening of UBE2S interacting protein and construction of prognostic model in hepatocellular carcinoma [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 168-177.
[12]	Xiaopeng YU,Renyi YANG,Zuomei HE,Puhua ZENG. Establishment and validation of nomogram of cancer specific survival of patients with hepatocellular carcinoma with negative alpha fetoprotein based on SEER Database [J]. Journal of Jilin University(Medicine Edition), 2024, 50(1): 188-197.
[13]	Yong DONG,Lingyao XU,Jing HUA,Han LIANG,Dongya LIU,Junbo ZHAO,Zhenglu SUN,Cheng CHENG,Shutang WEI. Effect of macrophage exosomal lncRNA HULC on migration, invasion，and metastasis of hepatocellular carcinoma cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1217-1226.
[14]	Wenjun DENG,Liantao HU,Binnan ZHAO,Xinyu DONG,Xuebin LI,Jie LI,Xinyan YANG,Xiaoli GUO,Yue LI,Yikun QU,Weiqun WANG. Effect of CXC chemokine ligand 10 on proliferation and migration of hepatocellular carcinoma SMMC-7721 cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1227-1233.
[15]	Yaqi XU,Yanyu WANG,Wenjing ZHANG,Mei HAN,Huaxia MU,Xi YANG,Weixiao BU,Zikun TAO,Yujia KONG,Fuyan SHI,Suzhen WANG. Bioinformatics analysis on screening of key genes of hepatitis B virus-related hepatocellular carcinoma and its relationship with prognosis [J]. Journal of Jilin University(Medicine Edition), 2023, 49(5): 1243-1252.